Clinical Trials Browser

neratinib × Tumor-Agnostic × 90 days × Clear all

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

Neoplasm Metastasis